Investment
Features
FeesSafety
Academy
More
Pluang+

Compare Oruka Therapeutics Inc. Common Stock (ORKA) vs Roundhill Innov-100 0DTE Covered Call Strat ETF (QDTE) Price & Performance

Oruka Therapeutics Inc. Common StockTrade
Roundhill Innov-100 0DTE Covered Call Strat ETFTrade

Price performance (Past 24H)

Key statistics

Oruka Therapeutics Inc. Common Stock vs Roundhill Innov-100 0DTE Covered Call Strat ETF — how do they compare? Oruka Therapeutics Inc. Common Stock trades at $76.8 (market cap $5.08B), while Roundhill Innov-100 0DTE Covered Call Strat ETF trades at $28.3 (market cap $948.83M). The key difference: Oruka Therapeutics Inc. Common Stock is far larger — about 5.4× Roundhill Innov-100 0DTE Covered Call Strat ETF's market cap, and Oruka Therapeutics Inc. Common Stock is trading nearer its 52-week high, Roundhill Innov-100 0DTE Covered Call Strat ETF nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold Oruka Therapeutics Inc. Common Stock for 0 Days and Roundhill Innov-100 0DTE Covered Call Strat ETF for 59 Days on average.

ORKAQDTE
Market Cap
$5.08B$948.83M
Volume
685,276442,852
Sector
HealthIncome / Options Overlay
52-Week High
$113.08$36.60
52-Week Low
$26.19$26.85
Typical Hold Time
0 Days59 Days
Enterprise Value
$4.21B—

Aura AI Summary

Signals from Pluang's Aura AI — not financial advice

Oruka Therapeutics Inc. Common Stock

No Aura AI signal available yet.

Roundhill Innov-100 0DTE Covered Call Strat ETF

QDTE (Roundhill Nasdaq-100 0DTE Covered Call Strategy ETF) trades at $29.29, down 0.14% with a bearish technical signal. The fund provides weekly distributions but faces criticism for yield sustainability and NAV erosion. Recent dividend payments have declined from $0.28 to $0.11, reflecting volatility compression. Technical indicators show mixed signals with neutral oscillators but bearish moving averages.

Outlook remains cautious due to structural concerns about return-of-capital distributions and underperformance in bull markets. The 24-31% yield appears unsustainable, with the fund sacrificing upside potential. Key risks include NAV decay, fee drag, and dependence on market volatility. Analyst sentiment has turned neutral to negative on the strategy's long-term viability.

Returns comparison

Trailing returns across standard periods

Investor sentiment on Pluang

What Pluang investors did over the last 30 days

ORKA
100% Buy0% Sell
Avg holding period · 0 Days
QDTE
100% Buy0% Sell
Avg holding period · 59 Days

About Oruka Therapeutics Inc. Common Stock

Oruka Therapeutics, Inc. is a clinical-stage biotechnology company developing extended half-life monoclonal antibodies for plaque psoriasis, psoriatic arthritis, and related dermatologic conditions, with lead candidates ORKA-001 and ORKA-002 in clinical trials.

Read more on ORKA →

About Roundhill Innov-100 0DTE Covered Call Strat ETF

QDTE is an actively managed ETF that seeks to generate income through a covered call strategy on the NASDAQ 100. It primarily holds a portfolio of U.S. government securities and sells 0-DTE (zero days to expiration) index call options on the NASDAQ 100. This highly tactical strategy aims to maximize option premium capture by exploiting the rapid time decay of options expiring on the same day, which provides enhanced income but also exposes the fund to significant volatility and risks associated with daily options settlement.

Read more on QDTE →